TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
6.1. Overview
6.2. Acute Hepatitis D
6.3. Chronic Hepatitis D
7. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT
7.1. Overview
7.2. Interferon Alpha
7.3. Lamivudine
7.4. Liver Transplant
7.5. Others
8. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS
8.1. Overview
8.2. Blood Tests
8.3. Elastography
8.4. Liver Biopsy
8.5. Serologic Testing
8.6. Others
9. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION
9.1. Overview
9.2. Exposure to Infected Blood
9.3. Contaminated Needles
9.4. Blood and Plasma Product Transfusion
9.5. Others
10. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS
10.1. Overview
10.2. Abdominal Pain
10.3. Jaundice
10.4. Joint Pain
10.5. Dark-Coloured Urine
10.6. Loss of Appetite
10.7. Fatigue
10.8. Nausea
10.9. Vomiting
11. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS
11.1. Overview
11.2. Clinic
11.3. Hospital
11.4. Others
12. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL
12.1. Overview
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
12.4. Online Pharmacy
13. GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION
13.1. Overview
13.1. North America
13.1.1. US
13.1.2. Canada
13.2. Europe
13.2.1. Germany
13.2.2. France
13.2.3. UK
13.2.4. Italy
13.2.5. Spain
13.2.6. Rest of Europe
13.3. Asia-Pacific
13.3.1. China
13.3.2. India
13.3.3. Japan
13.3.4. South Korea
13.3.5. Australia
13.3.6. Rest of Asia-Pacific
13.4. Rest of the World
13.4.1. Middle East
13.4.2. Africa
13.4.3. Latin America
14. COMPETITIVE LANDSCAPE
14.1. Overview
14.2. Competitive Analysis
14.3. Market Share Analysis
14.4. Major Growth Strategy in the Global Hepatitis Delta Virus (HDV) Infection Market,
14.5. Competitive Benchmarking
14.6. Leading Players in Terms of Number of Developments in the Global Hepatitis Delta Virus (HDV) Infection Market,
14.7. Key Developments and Growth Strategies
14.7.1. New Product Launch/Service Deployment
14.7.2. Merger & Acquisitions
14.7.3. Joint Ventures
14.8. Major Players Financial Matrix
14.8.1. Sales & Operating Income, 2023
14.8.2. Major Players R&D Expenditure. 2023
15. COMPANY PROFILES
15.1. BIOSIDUS.
15.1.1. Company Overview
15.1.2. Financial Overview
15.1.3. Products Offered
15.1.4. Key Developments
15.1.5. SWOT Analysis
15.1.6. Key Strategies
15.2. F. Hoffmann-La Roche Ltd.
15.2.1. Company Overview
15.2.2. Financial Overview
15.2.3. Products Offered
15.2.4. Key Developments
15.2.5. SWOT Analysis
15.2.6. Key Strategies
15.3. Zydus Cadila.
15.3.1. Company Overview
15.3.2. Financial Overview
15.3.3. Products Offered
15.3.4. Key Developments
15.3.5. SWOT Analysis
15.3.6. Key Strategies
15.4. NanoGen Healthcare Pvt. Ltd.
15.4.1. Company Overview
15.4.2. Financial Overview
15.4.3. Products Offered
15.4.4. Key Developments
15.4.5. SWOT Analysis
15.4.6. Key Strategies
15.5. AMEGA Biotech.
15.5.1. Company Overview
15.5.2. Financial Overview
15.5.3. Products Offered
15.5.4. Key Developments
15.5.5. SWOT Analysis
15.5.6. Key Strategies
15.6. Rhein-Minapharm
15.6.1. Company Overview
15.6.2. Financial Overview
15.6.3. Products Offered
15.6.4. Key Developments
15.6.5. SWOT Analysis
15.6.6. Key Strategies
15.7. PROBIOMED SA de CV
15.7.1. Company Overview
15.7.2. Financial Overview
15.7.3. Products Offered
15.7.4. Key Developments
15.7.5. SWOT Analysis
15.7.6. Key Strategies
15.8. 3SBio Group
15.8.1. Company Overview
15.8.2. Financial Overview
15.8.3. Products Offered
15.8.4. Key Developments
15.8.5. SWOT Analysis
15.8.6. Key Strategies
15.9. Eiger BioPharmaceuticals.
15.9.1. Company Overview
15.9.2. Financial Overview
15.9.3. Products Offered
15.9.4. Key Developments
15.9.5. SWOT Analysis
15.9.6. Key Strategies
15.10. Arrowhead Pharmaceuticals, Inc.
15.10.1. Company Overview
15.10.2. Financial Overview
15.10.3. Products Offered
15.10.4. Key Developments
15.10.5. SWOT Analysis
15.10.6. Key Strategies
16. APPENDIX
16.1. References
16.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 11 NORTH AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 12 NORTH AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 13 NORTH AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 14 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 15 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 16 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 17 US: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 18 US: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 19 US: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 20 US: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 21 US HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 22 US HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 23 US HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 24 CANADA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 25 CANADA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 26 CANADA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 27 CANADA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 28 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 29 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 30 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 4 EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 5 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 6 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 7 EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 8 GERMANY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 9 GERMANY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 10 GERMANY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 11 GERMANY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 12 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 13 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 14 GERMANY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 15 FRANCE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 16 FRANCE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 17 FRANCE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 18 FRANCE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 19 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 20 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 21 FRANCE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 ITALY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 23 ITALY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 24 ITALY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 25 ITALY: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 26 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 27 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 28 ITALY HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 29 SPAIN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 30 SPAIN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 31 SPAIN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 32 SPAIN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 33 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 34 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 35 SPAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 36 UK: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 37 UK: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 38 UK: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 39 UK: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 40 UK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 41 UK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 42 UK HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 43 REST OF EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 44 REST OF EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 45 REST OF EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 46 REST OF EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 47 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 48 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 49 REST OF EUROPE HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 50 ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 51 ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 52 ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 53 ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 54 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 55 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 56 ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 57 JAPAN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 58 JAPAN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 59 JAPAN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 60 JAPAN: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 61 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 62 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 63 JAPAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 64 CHINA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 65 CHINA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 66 CHINA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 67 CHINA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 68 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 69 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 70 CHINA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 71 INDIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 72 INDIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 73 INDIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 74 INDIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 75 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 76 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 77 INDIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 78 AUSTRALIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 79 AUSTRALIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 80 AUSTRALIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 81 AUSTRALIA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 82 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 83 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 84 AUSTRALIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 85 SOUTH KOREA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 86 SOUTH KOREA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 87 SOUTH KOREA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 88 SOUTH KOREA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 89 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 90 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 91 SOUTH KOREA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 92 REST OF ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 93 REST OF ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 94 REST OF ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 95 REST OF ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 96 REST OF ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 97 REST OF ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 98 REST OF ASIA-PACIFIC HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 99 REST OF THE WORLD: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 100 REST OF THE WORLD: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 101 REST OF THE WORLD: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 102 REST OF THE WORLD: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 103 REST OF THE WORLD HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 104 REST OF THE WORLD HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 105 REST OF THE WORLD HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 106 MIDDLE EAST: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 107 MIDDLE EAST: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 108 MIDDLE EAST: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 109 MIDDLE EAST: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 110 MIDDLE EAST HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 111 MIDDLE EAST HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 112 MIDDLE EAST HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 113 AFRICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 114 AFRICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 115 AFRICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 116 AFRICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 117 AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 118 AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
TABLE 119 AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 120 LATIN AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 121 LATIN AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
TABLE 122 LATIN AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DIAGNOSIS, 2019-2032 (USD BILLION)
TABLE 123 LATIN AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 124 LATIN AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2019-2032 (USD BILLION)
TABLE 125 LATIN AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY SYMPTOMS, 2019-2032 (USD BILLION)
TABLE 126 LATIN AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END-USERS, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 4 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY TYPE, 2023
FIGURE 5 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY TREATMENT, 2023
FIGURE 6 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY DIAGNOSIS, 2023
FIGURE 7 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY TRANSMISSION, 2023
FIGURE 8 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY SYMPTOMS, 2023
FIGURE 9 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY END-USERS, 2023
FIGURE 10 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 11 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 NORTH AMERICA: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY REGION, 2023
FIGURE 13 EUROPE: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY REGION, 2023
FIGURE 14 ASIA-PACIFIC: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY REGION, 2023
FIGURE 15 REST OF THE WORLD: HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, SHARE (%), BY REGION, 2023
FIGURE 16 GLOBAL HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 17 BIOSIDUS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 BIOSIDUS: SWOT ANALYSIS
FIGURE 19 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 21 ZYDUS CADILA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 ZYDUS CADILA: SWOT ANALYSIS
FIGURE 23 NANOGEN HEALTHCARE PVT. LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 NANOGEN HEALTHCARE PVT. LTD.: SWOT ANALYSIS
FIGURE 25 AMEGA BIOTECH.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 AMEGA BIOTECH.: SWOT ANALYSIS
FIGURE 27 ARROWHEAD PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 ARROWHEAD PHARMACEUTICALS, INC: SWOT ANALYSIS
FIGURE 29 RHEIN-MINAPHARM: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 RHEIN-MINAPHARM: SWOT ANALYSIS
FIGURE 31 PROBIOMED SA DE CV: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 PROBIOMED SA DE CV: SWOT ANALYSIS
FIGURE 33 3SBIO GROUP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 3SBIO GROUP: SWOT ANALYSIS
FIGURE 35 EIGER BIOPHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 EIGER BIOPHARMACEUTICALS: SWOT ANALYSIS
